X4 Pharmaceuticals is a biotechnology business based in the US. X4 Pharmaceuticals shares (XFOR) are listed on the NASDAQ and all prices are listed in US Dollars. X4 Pharmaceuticals employs 116 staff and has a market cap (total outstanding shares value) of 0.00.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $0.80 |
|---|---|
| 52-week range | $0.53 - $1.88 |
| 50-day moving average | $0.88 |
| 200-day moving average | $0.92 |
| Wall St. target price | $4.05 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.67 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.797 from 2024-07-22
| 1 week (2024-07-17) | 7.31% |
|---|---|
| 1 month (2024-06-24) | -21.09% |
| 3 months (2024-04-24) | -38.22% |
| 6 months (2024-01-24) | 10.69% |
| 1 year (2023-07-24) | -54.72% |
|---|---|
| 2 years (2022-07-22) | -33.03% |
| 3 years (2021-07-23) | 5.75 |
| 5 years (2019-07-24) | 12.51 |
| Gross profit TTM | $3 million |
|---|---|
| Return on assets TTM | -61.03% |
| Return on equity TTM | -489.12% |
| Profit margin | 0% |
| Book value | $0.01 |
| Market Capitalization | $127.5 million |
TTM: trailing 12 months
We're not expecting X4 Pharmaceuticals to pay a dividend over the next 12 months.
X4 Pharmaceuticals's shares were split on a 1:6 basis on 13 March 2019. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your X4 Pharmaceuticals shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for X4 Pharmaceuticals shares which in turn could have impacted X4 Pharmaceuticals's share price.
Over the last 12 months, X4 Pharmaceuticals's shares have ranged in value from as little as $0.531 up to $1.88. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while X4 Pharmaceuticals's is 0.348. This would suggest that X4 Pharmaceuticals's shares are less volatile than average (for this exchange).
X4 Pharmaceuticals, Inc. , a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia. The company is also developing X4P-003, a CXCR4 antagonist for the treatment of CXCR4 dependent disorders and primary immunodeficiencies; and X4P-002, a CXCR4 antagonist for the treatment of blood-brain barrier diseases. It has a license agreement with Abbisko Therapeutics Co Ltd. to develop, manufacture, and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston, Massachusetts.
Check out our picks of the best paper trading platforms to practice trading and investing with fake money.
Learn the basics of put options: what they are, how they work and a few examples.
A deep dive into the highlights and limitations of Frec.
Check out our picks for the brokers with the best cash sweep rates on uninvested cash.
These are the best day trading platforms, according to Finder’s comprehensive analysis.
Explore the best bonuses for opening a new brokerage account.
Looking for a discount broker like Webull that offers something different? Here are some of the top alternatives to consider.
What you need to know about investing in the leading indicator for the overall US stock market.
Check out our 7 ideas for how to invest $10K to maximize your money.
Check out the best-performing ETFs so far in 2024.